- Home
- AEE vs NTRA Comparison
AEE vs NTRA Comparison
Compare AEE & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEE
- NTRA
- Stock Information
- Founded
- AEE 1901
- NTRA 2003
- Country
- AEE United States
- NTRA United States
- Employees
- AEE N/A
- NTRA N/A
- Industry
- AEE Power Generation
- NTRA Medical Specialities
- Sector
- AEE Utilities
- NTRA Health Care
- Exchange
- AEE Nasdaq
- NTRA Nasdaq
- Market Cap
- AEE 27.3B
- NTRA 24.9B
- IPO Year
- AEE N/A
- NTRA 2015
- Fundamental
- Price
- AEE $103.94
- NTRA $172.64
- Analyst Decision
- AEE Buy
- NTRA Strong Buy
- Analyst Count
- AEE 9
- NTRA 17
- Target Price
- AEE $105.44
- NTRA $192.41
- AVG Volume (30 Days)
- AEE 1.5M
- NTRA 1.1M
- Earning Date
- AEE 11-05-2025
- NTRA 11-11-2025
- Dividend Yield
- AEE 2.74%
- NTRA N/A
- EPS Growth
- AEE 2.91
- NTRA N/A
- EPS
- AEE 4.55
- NTRA N/A
- Revenue
- AEE $8,119,000,000.00
- NTRA $1,964,250,000.00
- Revenue This Year
- AEE $16.32
- NTRA $24.28
- Revenue Next Year
- AEE $6.05
- NTRA $15.22
- P/E Ratio
- AEE $22.81
- NTRA N/A
- Revenue Growth
- AEE 17.75
- NTRA 44.38
- 52 Week Low
- AEE $85.27
- NTRA $117.27
- 52 Week High
- AEE $105.67
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- AEE 61.06
- NTRA 56.86
- Support Level
- AEE $103.22
- NTRA $157.43
- Resistance Level
- AEE $105.67
- NTRA $173.62
- Average True Range (ATR)
- AEE 1.28
- NTRA 5.16
- MACD
- AEE 0.26
- NTRA -0.10
- Stochastic Oscillator
- AEE 76.24
- NTRA 58.53
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and approximately 1 million natural gas customers accross its two service territories.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.